TLP
COGT icon

Tri Locum Partners’s Cogent Biosciences COGT Stock Holding History

Tri Locum Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-66,885
Closed -$792K – 66
2023
Q2 		$792K Buy
+66,885
New +$767K 0.29% 41

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Tri Locum Partners's COGT Position: Q3 2023 in Review

Tri Locum Partners sold out of Cogent Biosciences (COGT) in Q3 2023, closing a stake of 66,885 shares — an estimated $792K sold.

Tri Locum Partners first reported a position in COGT in Q2 2023 and held it in 1 quarter. The position peaked at $792K in Q2 2023. 135 funds tracked by Wall St. Rank hold COGT as of Q3 2023.

  • Tri Locum Partners reported no remaining Cogent Biosciences position as of Q3 2023 after selling out during the quarter.
  • Tri Locum Partners sold 66,885 Cogent Biosciences shares in Q3 2023, an estimated $792K.
  • Tri Locum Partners first reported a position in Cogent Biosciences in Q2 2023 and held it in 1 quarter.
  • Tri Locum Partners's Cogent Biosciences position peaked at $792K in Q2 2023.
  • 135 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2023.

Based on Tri Locum Partners's 13F filing for Q3 2023, filed 14 Nov 2023.